Hjem › Neuroblastom › Ohio › Columbus
Neuroblastom kliniske forsøg i Columbus, OH
5 studier for Neuroblastom søger deltagere på steder i og omkring Columbus (inden for ca. 30 miles). Åbn et studie for at se, hvem der kan deltage, og hvordan man kontakter studieteamet.
Officiel studietekst (engelsk)
Rekrutterer til et studie her? Få det vist øverst på siden — $99 i 30 dage →
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
RekruttererFase 3
- Nationwide Children's Hospital, Columbus
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
RekruttererFase 3
- Nationwide Children's Hospital, Columbus
NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
RekruttererFase 2
- Nationwide Children's Hospital, Columbus
Neuroblastoma Biology Study
RekruttererObservationsstudie
- Nationwide Children's Hospital, Columbus
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
RekruttererFase 2
- Nationwide Children's Hospital, Columbus
Neuroblastom forsøg i andre byer
- Boston, MA13 studier
- Washington, DC11 studier
- New York City, NY10 studier
- Dallas, TX9 studier
- Memphis, TN9 studier
- Philadelphia, PA9 studier
- St. Louis, MO9 studier
- Aurora, CO8 studier
- Hartford, CT8 studier
- Minneapolis, MN8 studier
- Birmingham, AL8 studier
- Atlanta, GA7 studier
Andre studier i Columbus
- Ikke-småcellet lungecancer56 studier
- Brystkræft39 studier
- Ægstockræft39 studier
- Kræft (alle typer)38 studier
- Lungecancer37 studier
- Akut myeloid leukæmi35 studier
- Kronisk lymfatisk leukæmi28 studier
- Metastatisk cancer27 studier
- Livmoderslimhindekræft25 studier
- Colorektal kræft24 studier
- Prostatakræft24 studier
- Multipelt myelom24 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.